Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00634751 · ClinicalTrials.gov registry record · Phase 1
CO07204-Phase I/II of Oxaliplatin, Capecitabine & Sorafenib for Advanced Pancreatic & Biliary Carcinoma
A Phase 1 study of Pancreatic Neoplasms and Bile Duct Neoplasms, sponsored by University of Wisconsin, Madison.
- Completed
- Registry status
- Phase 1
- Development phase
- 48
- Enrollment target
- 1
- Study location
NCT00634751 is a Phase 1 study of Pancreatic Neoplasms and Bile Duct Neoplasms that has completed, run by University of Wisconsin, Madison. The registered enrollment target is 48 participants, below the 600-participant average among 30 other Pancreatic Neoplasms trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00634751, a Phase 1 study of Pancreatic Neoplasms and Bile Duct Neoplasms, has completed, sponsored by University of Wisconsin, Madison.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 48 participants
- Enrollment target
- 1
- Study location
Study Summary
This study involves the use of oxaliplatin, capecitabine, and sorafenib which are all drugs approved by the Food and Drug Administration (FDA) for use in the treatment of different cancers. Their use in this exact combination is considered experimental for the treatment of pancreas and biliary tract; however the combination has been tested in a preliminary trial. We are also testing a survey designed. The purpose of this research study is to investigate the chemotherapy drug sorafenib in combination with oxaliplatin and capecitabine chemotherapies for the treatment of pancreas and biliary tract cancers.to help patients report their side effects from chemotherapy treatments.
Conditions Studied
Interventions
- DRUG Capecitabine
- DRUG Oxaliplatin
- DRUG Sorafenib
Study Locations (1)
Wisconsin
- University of Wisconsin - Madison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2008-02 |
| Est. Completion | 2010-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00634751
The ClinicalTrials.gov registry entry for NCT00634751 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 600-participant average among 30 other Pancreatic Neoplasms trials with a reported enrollment target (92% lower). The listed sponsor is University of Wisconsin, Madison, which has 1,039 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Pancreatic Neoplasms appearing as the primary indexed condition, and to 3 interventions - of which Capecitabine is the first listed.
NCT00634751 reports 1 study location spanning 1 distinct geographic area - top geographies include Wisconsin.
Frequently Asked Questions
What is clinical trial NCT00634751 about?
NCT00634751 is a clinical study titled "CO07204-Phase I/II of Oxaliplatin, Capecitabine & Sorafenib for Advanced Pancreatic & Biliary Carcinoma". This study involves the use of oxaliplatin, capecitabine, and sorafenib which are all drugs approved by the Food and Drug Administration (FDA) for use in the treatment of different cancers. Their use in this exact combination is considered experimental for the treatment of pancreas and biliary tract...
What is the current status of trial NCT00634751?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2008-02. Estimated completion is 2010-07.
What conditions does trial NCT00634751 study?
This clinical trial studies the following conditions: Pancreatic Neoplasms, Bile Duct Neoplasms.
What interventions are being tested in trial NCT00634751?
The interventions under investigation include: Capecitabine (DRUG), Oxaliplatin (DRUG), Sorafenib (DRUG).
Who is sponsoring clinical trial NCT00634751?
This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00634751 being conducted?
This trial has 1 study location across Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreatic Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma
RECRUITING · Phase 1
-
Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)
RECRUITING · Phase 1
-
A Study of PF-08046049/SGN-BB228 in Advanced Melanoma and Other Solid Tumors
ACTIVE NOT RECRUITING · Phase 1
-
A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Participants With Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression
ACTIVE NOT RECRUITING · Phase 1
-
A Study of Armed, Activated T-Cells in Patients With Advanced Pancreatic Cancer
ACTIVE NOT RECRUITING · Phase 1
-
Study of Safety and Efficacy of Glufosfamide in Combination With Gemcitabine in Cancer
COMPLETED · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.